World Scientific
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.

Formulating propranolol as an amorphous melt affords reduced skin irritation potential for transdermal drug delivery

    https://doi.org/10.1142/S2339547815500107Cited by:2 (Source: Crossref)

    Oral propranolol is commonly the first-line treatment of infantile hemangioma. However, oral delivery of propranolol is limited by systemic side effects, particularly in infants. Topical application may be a more patient friendly alternative while concurrently affording targeted delivery to the site of the skin lesion. Unfortunately, dose-dependent skin irritation is typically observed when propranolol is applied topically. Of additional concern, irritation is often exacerbated by organic solvents required to formulate propranolol. To address these concerns, we present novel formulations of propranolol as amorphous melts. Propranolol melts were successfully synthesized, and their physicochemical properties were tuned suitably for transdermal delivery using dialkyl sulfosuccinates as the counter species. Melts used in this study possessed the ability to penetrate skin when applied neat, without the need of any addition of solvent. Moreover, skin irritation potential of the lead melt was reduced compared to that of the propranolol free base (PFB). This reduction may be due to association of propranolol with the counter species in amorphous melts. The results presented here suggest amorphous melt formulations may open up the possibility to topically deliver drugs that traditionally elicit skin irritation.